Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment (HARMONY)
En fase 3, parallel-gruppebehandling, blindet, randomiseret, placebokontrolleret undersøgelse for at vurdere effektiviteten og sikkerheden af pegtibatinase administreret subkutant ud over standardbehandling hos deltagere med klassisk homocystinuri på grund af cystathionin beta-syntase-mangel (HMONY)
Researchers are looking for a better way to treat people living with classical homocystinuria (HCU), a rare inherited condition. It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme helps break down homocysteine, which is produced when the body processes methionine from protein-containing foods. This helps keep homocysteine and methionine at healthy levels. When this enzyme is not working, homocysteine and methionine build up in the blood and then spread into different tissues of the body and stop these body tissues from working normally.
People living with HCU can experience problems with their vision, bones, blood vessels, thinking, learning, and memory. Available treatments for HCU include a low-methionine diet (typically achieved by limiting protein-containing foods), a methionine-free protein supplement to help meet daily protein needs, and betaine (Cystadane®). These treatments are either not sufficient or are hard to take for many patients.
Pegtibatinase was designed by researchers to act like the CBS enzyme, which is missing or not working properly in people living with HCU. Researchers are studying whether adding pegtibatinase to standard treatment can lower homocysteine levels.
Researchers want to learn how safe and effective pegtibatinase is, how it moves through and affects the body, and how it may affect the daily lives of people with HCU.
The study plans to enroll participants from the US, Australia, Belgium, France, Germany, Ireland, Italy, Poland, Portugal, Qatar, Saudi Arabia, Spain, Turkey, and the United Kingdom. Many study visits may happen at home, depending on where you live and local regulations. Some visits may include a home nurse and telemedicine appointments with the study doctor.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Primary Objective:
Researchers want to learn more about how pegtibatinase will affect homocysteine and methionine levels when it is injected under the skin in participants already receiving standard treatment.
Blood tests will be used to measure changes in these levels during the study.
Secondary Objectives:
Researchers also want to learn:
- Is pegtibatinase safe and tolerable (how does it make participants feel)?
- How does pegtibatinase move throughout the body?
- Does pegtibatinase produce antibodies (proteins the body makes that may stop pegtibatinase from working or cause side effects)?
- How does pegtibatinase affect daily lives of participants with HCU? Researchers will use blood tests, urine tests, physical examinations, and questionnaires to answer these questions.
Study Population and Treatments:
This is a global study will include children and adults from 12 to 65 years old. Participants in the study will take their standard of care treatment. Participants will be put into 1 of 2 groups at random (like the flip of a coin) to take either:
- pegtibatinase, or
- an injection that does not have any medicine in it (or "placebo"). These are given as injections under the skin 2 times a week for up to 24 weeks. Neither the researchers nor the participant knows which treatment they are getting until the study is complete.
Study Duration and Visits:
Participants may be in the study for up to 38 weeks, including the screening period of up to 4 weeks, a pre-treatment period of up to 6 weeks where the participants will discuss their current diet with a dietitian (a health professional specialized in nutrition), a blinded treatment period of up to 24 weeks, and a safety follow-up visit completed 4 weeks after the last dose of study medication. Participants who complete the blinded treatment period may qualify to join the ENSEMBLE study before finishing the safety follow-up visit.
Participants who meet all study requirements may have up to 58 study visits. Visits may take place at a study center, at home, or by telemedicine.
These visits can include:
- Blood and urine tests
- Physical examinations
- Questionnaires
- Injections
- Questions about how they are feeling or any problems they are having
Safety / Adverse Events:
Researchers will monitor participants for any medical problems that occur during the study. Participants will have regular laboratory tests, health checkups, and study visits to monitor their health and safety.
Benefit-risk Conclusion:
Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Travere Call Center
- Telefonnummer: 1-877-659-5518
- E-mail: medinfo@travere.com
Studiesteder
-
-
-
Adelaide, Australien
- Rekruttering
- Royal Adelaide Hospital
-
Parkville, Australien
- Rekruttering
- Royal Children's Hospital Melbourne
-
Westmead, Australien
- Rekruttering
- Westmead Hospital
-
-
-
-
-
Brussels, Belgien
- Rekruttering
- Cliniques Universitaires Saint-Luc
-
Edegem, Belgien
- Rekruttering
- Universitair Ziekenhuis Antwerpen (UZA)
-
-
-
-
-
Birmingham, Det Forenede Kongerige
- Rekruttering
- Birmingham Women's and Children's NHS Foundation Trust
-
Birmingham, Det Forenede Kongerige
- Rekruttering
- University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
-
London, Det Forenede Kongerige
- Ikke rekrutterer endnu
- University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery
-
Salford, Det Forenede Kongerige
- Rekruttering
- Salford Royal NHS Foundation Trust - Salford Royal Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85006
- Rekruttering
- Phoenix Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06519
- Rekruttering
- Yale University School of Medicine
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Maine
-
Portland, Maine, Forenede Stater, 04102
- Rekruttering
- Maine Health - Maine Medical Center
-
-
Maryland
-
Chevy Chase, Maryland, Forenede Stater, 20815
- Rekruttering
- Uncommon Cures
-
-
New York
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- The Mount Sinai Hospital
-
-
North Carolina
-
Morrisville, North Carolina, Forenede Stater, 27560
- Rekruttering
- Science 37 - Virtual Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Ikke rekrutterer endnu
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84113
- Rekruttering
- Utah Health - The University of Utah Primary Children's Hospital
-
-
-
-
-
Paris, Frankrig
- Rekruttering
- Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades
-
Tours, Frankrig
- Rekruttering
- CHRU Hôpitaux de Tours - Hôpital Bretonneau
-
Vandœuvre-lès-Nancy, Frankrig
- Rekruttering
- Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants
-
-
-
-
-
Dublin, Irland
- Rekruttering
- Children's Health Ireland (CHI) at Temple Street
-
-
-
-
-
Bari, Italien
- Ikke rekrutterer endnu
- Ospedale Pediatrico Giovanni XXIII
-
Genova, Italien
- Ikke rekrutterer endnu
- IRCCS Istituto Giannina Gaslini
-
Milan, Italien
- Ikke rekrutterer endnu
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)
-
Monza, Italien
- Ikke rekrutterer endnu
- Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo
-
Padova, Italien
- Ikke rekrutterer endnu
- Azienda Ospedaliera di Padova
-
-
-
-
-
Krakow, Polen
- Ikke rekrutterer endnu
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Warsaw, Polen
- Rekruttering
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
Warsaw, Polen
- Ikke rekrutterer endnu
- Instytut Matki i Dziecka
-
-
-
-
-
Coimbra, Portugal
- Rekruttering
- Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra
-
Lisbon, Portugal
- Rekruttering
- Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria
-
Porto, Portugal
- Ikke rekrutterer endnu
- Unidade Local de Saúde de São João, EPE - Hospital São João
-
-
-
-
-
Doha, Qatar
- Rekruttering
- Hamad General Hospital
-
Doha, Qatar
- Rekruttering
- Sidra Hospital
-
-
-
-
-
Riyadh, Saudi Arabien
- Rekruttering
- King Abdullah International Medical Research Center
-
Riyadh, Saudi Arabien
- Rekruttering
- King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh
-
-
-
-
-
Barcelona, Spanien
- Rekruttering
- Hospital Sant Joan de Déu
-
Madrid, Spanien
- Rekruttering
- Hospital Universitario 12 de Octubre
-
Madrid, Spanien
- Rekruttering
- Hospital Universitario Ramón y Cajal
-
Santiago de Compostela, Spanien
- Rekruttering
- Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario
-
Seville, Spanien
- Rekruttering
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Ankara, Tyrkiet (Türkiye)
- Rekruttering
- Gazi University Hospital
-
Bornova, Tyrkiet (Türkiye)
- Ikke rekrutterer endnu
- Ege Üniversitesi Hastanesi Bornova
-
Istanbul, Tyrkiet (Türkiye)
- Ikke rekrutterer endnu
- Istanbul University Cerrahpasa Hospital
-
-
-
-
-
Hamburg, Tyskland
- Ikke rekrutterer endnu
- Universitätsklinikum Hamburg-Eppendorf
-
Leipzig, Tyskland
- Ikke rekrutterer endnu
- Universitätsklinikum Leipzig
-
Münster, Tyskland
- Ikke rekrutterer endnu
- Universitätsklinikum Münster
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Must be ≥12 to ≤65 years of age, at the time of signing the informed consent
- Must have a diagnosis of classical HCU based on clinical, biochemical, and/or molecular genetic testing
- Plasma tHcy ≥80 µM at Screening visit, with allowance for up to 18 participants who may be enrolled with a Screening plasma tHcy ≥50 to <80 µM
- Participants who can become pregnant must have a negative pregnancy test before starting the study and must use a highly effective form of birth control (less than 1% risk of pregnancy per year) during the study and for at least 4 weeks after the last dose.
- Willing to maintain a generally stable diet for the duration of the study (unless changes are required based on medical/safety reasons)
- Willing to maintain generally stable intake and doses of betaine, pyridoxine, and medical food for the duration of the study (unless changes are required based on medical/safety reasons)
Exclusion Criteria:
- Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or disorder of cobalamin metabolism
- Concurrent disease or condition (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease) that would interfere with study participation or safety (excluding complications of HCU).
- History of major thrombotic event (eg, cerebrovascular accident, myocardial infarction, pulmonary embolism) in the previous 6 months.
- Body weight ≥160 kg.
- Use or planned use of any injectable drugs containing PEG (excluding PEG-containing vaccines)
- Any previous exposure to pegtibatinase and/or previous participation in a clinical study that included administration of pegtibatinase or pegtarviliase
- Prior severe immune reaction to a PEG-containing product
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: placebo
|
volume-matched saline SC BIW |
|
Eksperimentel: pegtibatinase
|
Pegtibatinase BIW
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in plasma tHcy levels - Weeks 6 to 12
Tidsramme: Weeks 6 - 12
|
Change between baseline and average of 6 to 12 week (6, 8, 10, and 12 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy |
Weeks 6 - 12
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in plasma tHcy levels - Weeks 16 to 24
Tidsramme: Weeks 16 - 24
|
Change between baseline and average of 16 to 24 week (16, 20, and 24 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy |
Weeks 16 - 24
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Michael Imperiale, MD, Travere Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Metabolisme, medfødte fejl
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Bindevævssygdomme
- Hjernesygdomme, metaboliske, medfødte
- Hjernesygdomme, metaboliske
- Aminosyremetabolisme, medfødte fejl
- Hyperhomocysteinæmi
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Hud- og bindevævssygdomme
- Homocystinuri
Andre undersøgelses-id-numre
- TVTX-TVT058-301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
IPD-delingstidsramme
Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.
IPD-delingsadgangskriterier
Requires submission and approval of intended use and a data sharing agreement.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .